An interventional study of speech training and real tACS in Aphasia, sponsored by Ke Dong, MD. Completed at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Ke Dong, MD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Aphasia with a site in China — 10 open to participants now, 10 under way, none of them phase 3. Aphasia · China.
Among the 15 studies in Aphasia with a site in China, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 7 that started in 2023, is one of 13 with no phase, and was the 13th registered.
338 studies on the registry are indexed under Aphasia; 93 are open to participants now.
Browse Aphasia studies →10 of the 15 studies in Aphasia with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 20–80
The First Affiliated Hospital of Anhui Medical University · Sites in China
Ages 18–80
The First Affiliated Hospital of Anhui Medical University · Sites in China
Ages 18–80
Changping Laboratory · Sites in China
Ages 35–75
Changping Laboratory · Sites in China
Ages 35–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 66 Aphasia studies recruiting now, 30 (45%) set no upper age limit and 11 (17%) stop at 75 or younger; 1 takes children under 18; 16 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 7 started in 2023.
This study's enrollment of 28 is close to the median of 30 across 298 interventional studies indexed under Aphasia.
Median enrollment 50 across the 13 interventional studies, 65 across the 2 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 9 most frequent:
Ke Dong, MD is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Ke Dong, MD has 1 study filed under Aphasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Aphasia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07700537The First Affiliated Hospital of Anhui Medical UniversityEfficacy and Neural Mechanisms of Transcranial Direct Current Stimulation Targeting the Supplementary Motor Area for the Treatment of Subacute Post-stroke Aphasia | 2027-01-01 |
| NCT07346378The First Affiliated Hospital of Anhui Medical UniversityClinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke Aphasia | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Aphasia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to study whether dual-target transcranial alternating current stimulation (tACS) applied to the auditory and motor brain region can improve repetition disorder in people with stroke, and to evaluate the safety of tACS. The main goals are to answer the following questions:
Researchers will compare the effects of real tACS versus sham (placebo) stimulation to see if real stimulation leads to better outcomes in aphasia patients.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dual-target tACS on auditory and motor brain area at a frequency of 8 Hz,with individualized current intensity, delivered for 20 minutes.
Behavioral: speech training · Other: real tACS
sham tACS except for turning down the current intensity to zero during the 20-minute period, all other parameters are identical to those in real group.
Behavioral: speech training · Other: sham tACS
speech training(especially repetition training) synchronized with tACS stimulation
dual-target tACS on auditory and motor brain area at a frequency of 8 Hz,with individualized current intensity, delivered for 20 minutes.
except for turning down the current intensity to zero during the 20-minute period, all other parameters are identical to those in real group.
Western Aphasia Battery (WAB) score
Western Aphasia Battery (WAB) score:0-100,higher score means better language function
Time frame: Baseline and 10-days
Ran from Jan 2023 to primary completion in Dec 2025, 35 months.
Of 183 non-industry interventional studies with no phase under Aphasia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's 35 months is close to that.
Counting every sponsor, half of 185 studies reached it within 36 months; a quarter within 19 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ke Dong, MD